D+Q · Senolytic Stack · Dasatinib Quercetin
Dasatinib plus Quercetin (D+Q) is a senolytic combination therapy developed at the Mayo Clinic by Drs. James Kirkland and Tamara Tchkonia. Dasatinib is an FDA-approved tyrosine kinase inhibitor (brand name Sprycel) used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. Quercetin is a naturally occurring flavonoid found in fruits, vegetables, and supplements. Together, they selectively target and eliminate senescent cells - damaged cells that have stopped dividing but resist apoptosis and secrete a toxic mix of inflammatory factors known as the senescence-associated secretory phenotype (SASP).
Starting dose. D 100mg + Q 1000mg
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
Dasatinib inhibits multiple tyrosine kinases (Src family kinases, BCR-ABL, ephrin receptors) that senescent cells depend on for survival signaling. By blocking these pro-survival pathways (particularly the Src/PI3K/AKT axis), dasatinib pushes senescent preadipocytes and other mesenchymal senescent cells toward apoptosis.
Quercetin inhibits PI3K, serpins (particularly PAI-2), and BCL-2 family anti-apoptotic proteins that protect senescent endothelial cells and bone marrow stem cells from programmed cell death. It also has broad anti-inflammatory and antioxidant properties that complement its senolytic activity.
The combination exploits the fact that different senescent cell types rely on different anti-apoptotic networks (SCAPs - Senescent Cell Anti-apoptotic Pathways). By targeting multiple SCAPs simultaneously, D+Q achieves broader senescent cell clearance than either compound alone.
Days 1-7: Senescent cell apoptosis initiated during dosing days. SASP factor reduction measurable within days. Possible transient side effects (GI, fatigue) during dosing.
Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.
Adults with diabetic kidney disease received oral dasatinib 100 mg plus quercetin 1,000 mg for three days.
In an open label Phase 1 pilot study, we administered 3 days of oral D 100 mg and Q 1000 mg to subjects with diabetic kidney disease (N = 9; 68·7 ± 3·1 years old; 2 female; BMI:33·9 ± 2·3 kg/m2; eGFR:27·0 ± 2·1 mL/min/1·73m2).
Evidence scope. Open-label Phase I pilot in nine older adults; supports one three-day course, not monthly repetition or healthy-person use.
D+Q senolytics selectively eliminate senescent cells by transiently disabling their pro-survival networks.
Senolytics, including the combination of Dasatinib and Quercetin (D + Q), selectively eliminate senescent cells by transiently disabling pro-survival networks that defend them against their own apoptotic environment.
Evidence scope. Exact human combination; supports the high-level senolytic mechanism, not every individual pathway listed on the page.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Repeated frequency: 2-3 consecutive days every month. The exact-dose abstract reports one three-day course, not monthly repeat cycling.
Primary safety: GI symptoms, fatigue, myelosuppression, and pleural effusion at D 100 mg + Q 1,000 mg. No checked abstract stated this full safety profile at the exact regimen. PMID 36857968 used Q 1,250 mg and a different schedule.
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
D: ~4 hours, Q: ~3.5 hours
D: ~1-2 hours oral, Q: ~1-3 hours oral
D: ~20 hours, Q: ~18 hours
D: ~14-34% oral, Q: ~2% oral (improved with fat)
Days to weeks (senolytic cell death is triggered during dosing window; SASP reduction measurable for weeks after a single course)
D: Hepatic (CYP3A4 metabolism, fecal excretion); Q: Hepatic (glucuronidation and sulfation, renal excretion)
Storage. Dasatinib: store at room temperature 20-25C (68-77F). Quercetin: store in cool, dry place. No refrigeration needed for either compound in oral form.
Dasatinib is FDA-approved for CML and Ph+ ALL (not for senolytic use). Quercetin is a dietary supplement (no FDA approval needed). The D+Q senolytic combination is investigational and not approved for any anti-aging indication. Multiple clinical trials ongoing (ClinicalTrials.gov).
Put it to work
Open Dasatinib+Quercetin straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Dasatinib+Quercetin in the app →Go deeper
The complete Dasatinib+Quercetin walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗Track it in OnePin. Log vials, draws, and protocols in the app.
Type a name, brand, or tool. Esc closes.